SEARCH

SEARCH BY CITATION

References

  • 1
    Shimomura T, Denda K, Kitamura A et al. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J Biol Chem 1997; 272: 63706.
  • 2
    Kataoka H, Suganuma T, Shimomura T et al. Distribution of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in human tissues. Cellular surface localization of HAI-1 in simple columnar epithelium and its modulated expression in injured and regenerative tissues. J Histochem Cytochem 1999; 47: 67382.
  • 3
    Kataoka H. SPINT1 (serine peptidase inhibitor, Kunitz type 1). Atlas Genet Cytogenet Oncol Haematol 2009. [Cited October 14, 2010.] Available from URL: http://AtlasGeneticsOncology.org/Genes/SPINT1ID44384ch15q15.html
  • 4
    Kataoka H, Shimomura T, Kawaguchi T et al. Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment. J Biol Chem 2000; 275: 4045362.
  • 5
    Shimomura T, Denda K, Kawaguchi T, Matsumoto K, Miyazawa K, Kitamura N. Multiple sites of proteolytic cleavage to release soluble forms of hepatocyte growth factor activator inhibitor type 1 from a transmembrane form. J Biochem 1999; 126: 8218.
  • 6
    Denda K, Shimomura T, Kawaguchi T, Miyazawa K, Kitamura N. Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 1. J Biol Chem 2002; 277: 140539.
  • 7
    Eigenbrot C, Ganesan R, Kirchhofer D. Hepatocyte growth factor activator (HGFA): molecular structure and interactions with HGFA inhibitor-1 (HAI-1). Febs J 2010; 277: 221522.
  • 8
    Bugge TH, Antalis TM, Wu Q. Type II transmembrane serine proteases. J Biol Chem 2009; 284: 2317781.
  • 9
    Cheng H, Fukushima T, Takahashi N, Tanaka H, Kataoka H. Hepatocyte growth factor activator inhibitor type 1 regulates epithelial to mesenchymal transition through membrane-bound serine proteinases. Cancer Res 2009; 69: 182835.
  • 10
    Kataoka H, Kawaguchi M. Hepatocyte growth factor activator (HGFA): pathophysiological functions in vivo. Febs J 2010; 277: 22307.
  • 11
    Mukai S, Fukushima T, Naka D, Tanaka H, Osada Y, Kataoka H. Activation of hepatocyte growth factor activator zymogen (pro-HGFA) by human kallikrein 1-related peptidases. Febs J 2008; 275: 100317.
  • 12
    Iwamura T, Katsuki T, Ide K. Establishment and characterization of a human pancreatic cancer cell line (SUIT-2) producing carcinoembryonic antigen and carbohydrate antigen 19-9. Jpn J Cancer Res 1987; 78: 5462.
  • 13
    Kataoka H, Itoh H, Seguchi K, Koono M. Establishment and characterization of a human lung adenocarcinoma cell line (LC-2/ad) producing a1-antitrypsin in vitro. Acta Pathol Jpn 1993; 43: 56673.
  • 14
    Fukushima T, Tezuka T, Shimomura T, Nakano S, Kataoka H. Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24. J Biol Chem 2007; 282: 1863444.
  • 15
    Betsunoh H, Mukai S, Akiyama Y et al. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. Cancer Sci 2007; 98: 4918.
  • 16
    Tsujimoto M, Nakabayashi K, Yoshidome K et al. One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res 2007; 13: 480716.
  • 17
    Tamaki Y, Akiyama F, Iwase T et al. Molecular detection of lymph node metastases in breast cancer patients: results of a multicenter trial using the one-step nucleic acid amplification assay. Clin Cancer Res 2009; 15: 287984.
  • 18
    Li W, Wang BE, Moran P et al. Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis. Cancer Res 2009; 69: 8395402.
  • 19
    Saleem M, Adhami VM, Zhong W et al. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev 2006; 15: 21727.
  • 20
    Parr C, Watkins G, Mansel RE, Jiang WG. The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 2004; 10: 20211.
  • 21
    Zeng L, Cao J, Zhang X. Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract. World J Gastroenterol 2005; 11: 62027.
  • 22
    Nakamura K, Abarzua F, Hongo A et al. The role of hepatocyte growth factor activator inhibitor-1 (HAI-1) as a prognostic indicator in cervical cancer. Int J Oncol 2009; 35: 23948.
  • 23
    Nakamura K, Hongo A, Kodama J, Hiramatsu Y. The role of hepatocyte growth factor activator inhibitor (HAI)-1 and HAI-2 in endometrial cancer. Int J Cancer (in press) doi: 10.1002/ijc.25606.
  • 24
    Parr C, Jiang WG. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells. Int J Cancer 2006; 119: 117683.
  • 25
    Sanders AJ, Parr C, Mason MD, Jiang WG. Suppression of hepatocyte growth factor activator inhibitor-1 leads to a more aggressive phenotype of prostate cancer cells in vitro. Int J Mol Med 2007; 20: 6139.
  • 26
    Miyata S, Fukushima T, Kohama K, Tanaka H, Takeshima H, Kataoka H. Roles of Kunitz domains in the anti-invasive effect of hepatocyte growth factor activator inhibitor type 1 in human glioblastoma cells. Hum Cell 2007; 20: 1006.
  • 27
    Tomioka D, Maehara N, Kuba K et al. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res 2001; 61: 751824.